Are selective COX-2 inhibitors a safe option in patients with intolerance to nonsteroidal antiinflammatory drugs?
Quiñones Estévez
Ma Dolores
MD
Departamento de Alergología, Hospital Monte Naranco, Oviedo, Spain. quinonesd@orange.es
D000328:Adult; D000368:Aged; D000799:Angioedema / Q000276:immunology; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000009:adverse effects*; D051546:Cyclooxygenase 2 / Q000276:immunology / Q000378:metabolism*; D052246:Cyclooxygenase 2 Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D004342:Drug Hypersensitivity / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D004361:Drug Tolerance; D005076:Exanthema / Q000276:immunology; D005260:Female; D006801:Humans; D000077239:Meloxicam; D008875:Middle Aged; D012189:Retrospective Studies; D012882:Skin Tests; D013843:Thiazines / Q000008:administration & dosage / Q000009:adverse effects; D013844:Thiazoles / Q000008:administration & dosage / Q000009:adverse effects
D000894:Anti-Inflammatory Agents, Non-Steroidal; D052246:Cyclooxygenase 2 Inhibitors; D013843:Thiazines; D013844:Thiazoles; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; D000077239:Meloxicam